Prasol Chemicals
FinMinutes Deep Business Model & Edge
Prasol Chemicals Limited is a forward integrated manufacturer of acetone and phosphorus-based specialty chemicals, as well as other specialty chemicals involving complex and differentiated chemistries. Established in 1992, the company serves a diversified customer base across domestic and international markets, exporting to 69 countries as of July 15, 2026.
What this company actually does — full breakdown ▾
Prasol Chemicals Limited, established in 1992, is a leading forward-integrated manufacturer of acetone and phosphorus-based specialty chemicals, as well as other customized specialty chemicals involving complex and differentiated chemistries. The company operates two automated manufacturing facilities in Khopoli and Mahad, Maharashtra, with an aggregate installed capacity of 98,644 metric tonnes per annum as of June 30, 2026. The company’s comprehensive product portfolio includes over 150 specialty chemical products, consisting of 21 acetone-based specialty chemicals (such as diacetone alcohol, isophorone, and hexylene glycol), 53 phosphorus-based specialty chemicals (such as phosphorus pentasulphide and polyphosphoric acid), and 76 other customized specialty products (including surfactants, performance additives, ethers, esters, polymers, and acids). Prasol is the sole manufacturer of isophorone in India with a capacity of 9,000 MTPA. It caters to a highly diversified customer base of 1,618 customers in Fiscal 2026 across major application industries including performance chemicals, paints, inks, construction and adhesives (PICA), pharmaceuticals, agrochemicals, and home and personal care. The company possesses a robust global footprint, exporting to 69 countries across the Asia-Pacific region, North America, South America, and Europe. It is also the largest importer of acetone and among the top five importers and users of yellow phosphorus in India.
- Acetone-based specialty chemicals — The company is the largest importer of acetone in India to produce a highly diversified range of acetone derivatives such as diacetone alcohol, isophorone, and hexylene glycol, and is the only manufacturer of isophorone in India with a capacity of 9,000 MTPA.
- Phosphorus-based specialty chemicals — Among the top five importers and users of yellow phosphorus in India, producing derivatives such as phosphorus pentasulphide, phosphorus pentoxide, polyphosphoric acid, and Dithio-phosphates for lubricant additives and mining.
- Other specialty chemicals — Includes non-acetone and non-phosphorus based customized specialty chemicals such as surfactants, performance additives, ethers, esters, polymers, and acids.
Prasol's competitive moat is driven by its position as the sole manufacturer of isophorone in India (9,000 MTPA capacity) and the largest importer and consumer of acetone in India, resulting in limited domestic competition. Additionally, the industry has high entry barriers, including a lengthy customer registration and qualification process of 1-4 years, and the company benefits from strong application-driven R&D capabilities and backward integration.
The Offer
Follow the Money — Use of Proceeds
- Repayment or pre-payment, in full or in part, of certain of our outstanding borrowings availed by our Company — ₹60.00 cr
- General corporate purposes
Valuation at the Offer Price
The filing does not print a single headline multiple, so this one is ours: the upper band divided by the latest restated earnings per share — the same arithmetic the “Basis for the Offer Price” section performs. It is struck on pre-issue earnings, so the post-issue figure will differ once the fresh capital is deployed. The peer group is the one the filing itself names. A premium is not the same thing as expensive and a discount is not the same thing as cheap — the peer table and the reasons sit further down this page.
FinMinutes IPO Score — How It's Built
Transparent, deterministic, computed from the filing — not an opinion. Open any component below to see exactly what it measures and what it is worth. Components with no disclosed input are dropped from the weighting entirely rather than held at an invented neutral, because a constant inside a weighted average is not neutral — it quietly drags every score toward the middle. Weighted across 6 live components.
100% of the designed weighting had real data behind it on this issue. A lower coverage figure does not mean a worse company — it means we are standing behind less of the picture, and you should read the findings below rather than the headline number.
How this is measured12%
Whether fresh capital actually enters the business. A predominantly offer-for-sale issue is marked down ONLY when the financials are weak. A profitable, cash-rich company selling down is treated as neutral, not penalised, because it does not need the money.
How this is measured12%
What changed between the draft prospectus and the final one. A period roll-forward or a refreshed industry report is expected and scores neutral. A statutory auditor replaced mid-process, a prior year restated, an offer-for-sale expanded late, new statutory dues disclosed, or a risk factor quietly removed all score against. Where only one of the two documents has been read, this component is dropped from the weighting rather than guessed.
How this is measured32%
Driven by the models battery run on the filing's own restated numbers: the Piotroski fundamental tests (scored out of those we could actually run), the Altman Z-double-prime solvency zone, and the direction of profit across the disclosed period. It is not a single yes/no on last year's profit.
How this is measured10%
The post-issue earnings multiple against the peer median disclosed in the filing. A discount to the median scores well and a premium scores badly. When the filing does not disclose comparable peer multiples, this component is dropped from the weighting rather than held at a made-up neutral.
How this is measured6%
A proxy for syndicate strength, based today only on how many lead managers are on the issue: 75 where three or more banks are involved, 60 otherwise. We have not built a bank-by-bank track record, so treat this as a rough signal. When the filing does not disclose the syndicate, this component is dropped from the weighting rather than guessed.
How this is measured28%
Starts at 100 and loses points for every material finding: 12 for a flagged finding, 4 for a noted one. Two kinds feed it. DERIVED findings are computed from the filed numbers against stated thresholds — operating cash negative while profit is positive, related-party revenue above 15% of total, revenue rising while profit falls, goodwill above 30% of net worth, receivables growing more than 1.3x faster than sales, cash below half of short-term debt. Those are reproducible: the same filing gives the same answer every time, and the rule is printed beside the finding. READ findings come from the forensic sweep of the notes. Contingent liabilities, related-party intensity, customer concentration, litigation, auditor qualifications, statutory dues, promoter funding. Findings that record the ABSENCE of a problem — no litigation pending, an unmodified audit opinion — deduct nothing. This is the component our forensic read drives directly, and it moves most between companies.
3-Year Financial & Growth Trend
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue (₹ Cr) | 1232.593 | 1012.494 | 876.565 |
| Net Profit (₹ Cr) | 83.124 | 43.569 | 18.131 |
| PAT Margin | 6.74% | 4.3% | 2.07% |
Revenue Breakdown
- Acetone based specialty chemicals: 42.75%
- Phosphorous based specialty chemicals: 38.3%
- Other specialty chemicals: 18.33%
- Other operating and service revenue: 0.62%
Deep Financials
Revenue, EBITDA and profit are what every listing site prints. Below are the full restated statements as disclosed, the ratios we compute from them, and a DuPont decomposition of the return on equity. A prospectus carries three years, not ten — that is the document’s ceiling, and within it we go as deep as it allows.
Income StatementThe profit and loss as filed, then what we derive from it — kept apart.
Statutory order, exactly as restated in the filing. Finance cost and depreciation sit inside Total Expenses under Ind AS, which is why they are listed among the expense lines here rather than below the total. The expense rows sum to the total. Rows the filing does not disclose separately are omitted rather than left blank.
| Income Statement — as filed (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue from Operations | 1,232.59 | 1,012.49 | 876.57 |
| Other Income | 5.25 | 3.05 | 11.00 |
| Total Income | 1,237.85 | 1,015.54 | 887.56 |
| Cost of Materials Consumed | 688.47 | 607.60 | 517.40 |
| Purchases of Stock-in-Trade | 175.09 | 134.31 | 136.49 |
| Changes in Inventories | -9.65 | -17.56 | -6.07 |
| Employee Benefit Expense | 50.37 | 41.70 | 32.83 |
| Finance Cost | 7.98 | 8.25 | 10.89 |
| Depreciation & Amortisation | 24.70 | 23.28 | 21.36 |
| Other Expenses | 189.00 | 158.68 | 135.37 |
| Total Expenses | 1,125.95 | 956.25 | 848.28 |
| Profit Before Exceptional Items and Tax | 111.90 | 59.29 | 39.29 |
| Exceptional Items | — | — | -5.76 |
| Share of Profit of Associates / JV | — | — | -0.01 |
| Profit Before Tax | 111.90 | 59.29 | 33.51 |
| Tax Expense | 28.78 | 15.72 | 15.38 |
| Profit After Tax | 83.12 | 43.57 | 18.13 |
| Other Comprehensive Income | -0.35 | -0.21 | 0.23 |
| Total Comprehensive Income | 82.78 | 43.36 | 18.36 |
| EPS - Basic | 14.33 | 7.51 | 3.13 |
| EPS - Diluted | 14.33 | 7.51 | 3.13 |
Balance SheetWhat the company owns, owes, and is worth on paper.
| Balance Sheet (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Share Capital | 11.60 | 11.60 | 11.60 |
| Reserves & Surplus | 436.91 | 355.87 | 314.24 |
| Net Worth | 448.51 | 367.47 | 325.84 |
| Long-term Borrowings | 47.00 | 43.58 | 42.84 |
| Short-term Borrowings | 63.06 | 57.47 | 39.23 |
| Total Borrowings | 110.06 | 101.05 | 82.07 |
| Trade Payables | 208.24 | 196.87 | 171.26 |
| Current Liabilities | 307.71 | 278.55 | 230.78 |
| Total Liabilities | 390.77 | 355.62 | 300.52 |
| Property, Plant & Equipment | 311.01 | 324.44 | 324.48 |
| Capital Work in Progress | 47.08 | 21.22 | 21.67 |
| Intangible Assets | 3.10 | 1.64 | 1.85 |
| Investments | 0.00 | 0.00 | 0.04 |
| Inventories | 153.24 | 151.70 | 99.83 |
| Trade Receivables | 278.69 | 197.27 | 160.34 |
| Cash & Equivalents | 24.07 | 16.65 | 9.97 |
| Current Assets | 474.21 | 372.98 | 275.53 |
| Total Assets | 839.28 | 723.09 | 626.36 |
Cash FlowWhere the cash actually went. Often the most honest statement of the three.
| Cash Flow (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Cash from Operating Activities | 49.47 | 22.26 | 115.61 |
| Capital Expenditure | 39.00 | 22.58 | 19.14 |
| Net Cash from Investing Activities | -38.43 | -22.48 | -17.90 |
| Net Cash from Financing Activities | 0.14 | 10.23 | -115.11 |
| Net Change in Cash | 7.42 | 6.69 | -11.07 |
Ratio AnalysisProfitability, leverage, liquidity, efficiency and earnings quality — computed by us.
Every ratio below is computed by us from the line items the company disclosed — not copied from anywhere. The arithmetic is standard; the point is that somebody actually did it. Blank cells mean the filing did not disclose the inputs, and we would rather show a gap than invent a number.
| Ratio | FY26 | FY25 | FY24 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin (%) | 11.7 | 8.9 | 8.1 |
| EBIT Margin (%) | 9.7 | 6.7 | 5.7 |
| PAT Margin (%) | 6.7 | 4.3 | 2.1 |
| Return on Equity (%) | 18.5 | 11.9 | 5.6 |
| Return on Capital Employed (%) | 21.5 | 14.4 | 12.3 |
| Return on Assets (%) | 9.9 | 6 | 2.9 |
| Leverage | |||
| Debt / Equity (x) | 0.25 | 0.27 | 0.25 |
| Net Debt / EBITDA (x) | 0.59 | 0.93 | 1.01 |
| Interest Coverage (x) | 15.03 | 8.19 | 4.61 |
| Liquidity | |||
| Current Ratio (x) | 1.54 | 1.34 | 1.19 |
| Quick Ratio (x) | 1.04 | 0.79 | 0.76 |
| Efficiency | |||
| Asset Turnover (x) | 1.47 | 1.4 | 1.4 |
| Receivable Days | 83 | 71 | 67 |
| Inventory Days | 45 | 55 | 42 |
| Payable Days | 62 | 71 | 71 |
| Cash Conversion Cycle (days) | 66 | 55 | 38 |
| Quality of Earnings | |||
| Operating Cash Flow / PAT (x) | 0.6 | 0.51 | 6.38 |
| Accruals Ratio (%) | 4 | 2.9 | -15.6 |
| Capex / Depreciation (x) | 1.58 | 0.97 | 0.9 |
DuPont DecompositionWhy the return on equity is what it is: margin, efficiency, or leverage.
A headline return on equity tells you what. The DuPont decomposition tells you why — whether the return is earned through margin, through asset efficiency, or simply through leverage. Two companies can post an identical ROE for opposite reasons, and only one of them is safe.
| Component | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Margin (PAT / Revenue) | 6.7% | 4.3% | 2.1% |
| Asset Turnover (Revenue / Assets) | 1.47x | 1.4x | 1.4x |
| Equity Multiplier (Assets / Net Worth) | 1.87x | 1.97x | 1.92x |
| = Return on Equity | 18.5% | 11.9% | 5.6% |
| Tax Burden (PAT / PBT) | 0.74x | 0.73x | 0.54x |
| Interest Burden (PBT / EBIT) | 0.93x | 0.88x | 0.67x |
| Operating Margin (EBIT / Revenue) | 9.7% | 6.7% | 5.7% |
Computed from the disclosed statements. Where the filing omits an input, the row is left blank rather than estimated.
Quality of EarningsWhat the statements say when you read them against each other.
What the statements say once you read them against each other. These are observations, not verdicts — every one is arithmetic on the numbers the company itself disclosed, and each is stated so you can go and check it in the filing.
- Between FY24 and FY26 revenue grew 41% while profit grew 358%. Profit expanding at several times the rate of revenue is not automatically a concern — operating leverage does exactly this — but it is worth confirming from the filing whether the gap comes from genuine margin expansion or from one-off items.
- Interest coverage was 15.03x in FY26. Debt servicing is comfortably covered by operating profit.
Forensic ModelsBeneish, Altman and Piotroski — plus our own final-year check.
Beneish M-Score
M = -1.66An eight-variable model built to detect earnings manipulation, and built to run on exactly two consecutive years — which is what a prospectus gives us. It belongs here more than anywhere: a company about to list has the maximum possible incentive to have dressed up the very years it is about to show you. A score above −1.78 is the threshold at which the model says the accounts merit a closer look. It is a screening signal, not an accusation, and it was calibrated on listed companies elsewhere. Read the eight components, not just the total.
| Component | Value | What it captures |
|---|---|---|
| DSRI Days Sales in Receivables Index (Receivables_t / Sales_t) / (Receivables_t-1 / Sales_t-1) | 1.16 | Above 1 means receivables grew faster than sales. Revenue may be being recognised ahead of collection. |
| GMI Gross Margin Index GrossMargin_t-1 / GrossMargin_t | 0.906 | Above 1 means margins deteriorated. A firm with worsening prospects has more incentive to manipulate. |
| AQI Asset Quality Index AQ_t / AQ_t-1, where AQ = 1 - (CurrentAssets + PPE) / TotalAssets | 1.814 | Above 1 means a rising share of assets is soft (neither current nor fixed) — capitalised costs can hide here. |
| SGI Sales Growth Index Sales_t / Sales_t-1 | 1.217 | Growth is not manipulation. But high-growth firms face more pressure to keep the streak going. |
| DEPI Depreciation Index DepRate_t-1 / DepRate_t, where DepRate = Dep / (Dep + PPE) | 0.91 | Above 1 means assets are being depreciated more slowly — a quiet way to lift reported profit. |
| SGAI SG&A Index (SGA_t / Sales_t) / (SGA_t-1 / Sales_t-1), SGA proxied as employee cost + other expenses | 0.981 | A proxy, because filings rarely break out SG&A cleanly. Read it as a direction, not a precise figure. |
| LVGI Leverage Index Leverage_t / Leverage_t-1, where Leverage = (CurrentLiab + LongTermDebt) / TotalAssets | 0.949 | Above 1 means leverage rose. Debt covenants create pressure to hit numbers. |
| TATA Total Accruals to Total Assets (PAT - CashFromOperations) / TotalAssets | 0.0401 | The gap between reported profit and cash generated. The single heaviest term in the model — and the one that catches profit that never became cash. |
This score is driven primarily by the sales-growth term (SGI). Growth is the one variable in this model that is not itself a manipulation signal — the model treats rapid growth as pressure to keep the streak going, not as evidence of anything. A company that grew revenue several-fold will read high here for that reason alone. The variable that speaks to manipulation directly is TATA (accruals — profit that did not become cash); read that one, and the receivables trend, rather than the headline M.
M = -1.66, above the −1.78 threshold. On this model the accounts merit closer reading. That is a prompt to go to the filing, not a conclusion about it.
Altman Z″-Score (emerging markets)
Z″ = 8.41 · SafeA distress-prediction model. We use the Z″ variant deliberately: the original Z was calibrated on American manufacturers and misleads badly on Indian services companies. Above 2.6 is the safe zone, 1.1 to 2.6 is grey, below 1.1 is the distress zone. Like every model of its kind it is a screen, not a prophecy.
| X1 — Working Capital / Total Assets | 0.198 |
| X2 — Retained Earnings / Total Assets | 0.521 |
| X3 — EBIT / Total Assets | 0.143 |
| X4 — Net Worth / Total Liabilities | 1.148 |
| Z″ = 3.25 + 6.56·X1 + 3.26·X2 + 6.72·X3 + 1.05·X4 | 8.41 |
Piotroski F-Score (adapted)
7 / 8Nine yes-or-no tests of fundamental strength — except we run eight. One of the original nine asks whether the company issued new shares, which is plainly absurd to ask of a company whose entire purpose at this moment is to issue shares. We drop that test and score out of eight, and we would rather tell you that than quietly fudge it.
- ✓Positive return on assets
- ✓Positive operating cash flow
- ✓Return on assets improving
- ✗Cash flow exceeds profit (quality of earnings)
- ✓Long-term leverage decreasing
- ✓Current ratio improving
- ✓Gross margin improving
- ✓Asset turnover improving
Ratios Nobody Prints
- Contingent liabilities / Net worth: 2.2%
Contingent liabilities of 10.02 cr against a net worth of 448.51 cr — 2.2% of what the company is worth on paper. These are obligations that sit off the balance sheet but could land on it. What they consist of matters as much as the size: a corporate guarantee to a subsidiary is a different animal from a disputed tax demand, and the filing says which. - Related-party revenue / Total revenue: 0%
0% of revenue in FY26 came from entities connected to the promoters. Revenue you sell to yourself is not the same as revenue you won in the market. - Cash / Short-term borrowings: 0.38x
Short-term borrowings of 63.06 cr against cash of 24.07 cr. Debt that must be refinanced within a year is only comfortable while lenders stay comfortable. - Promoter remuneration / PAT: 14.7%
Managerial remuneration to the promoter group was 12.19 cr against a profit of 83.12 cr. This is a legitimate cost — but it is also a route by which value leaves a company before it ever reaches a minority shareholder.
The Formula NotebookEvery number above, with the working shown. Check us.
Every number we publish, with the working shown. The formula, the same formula with this company’s actual figures put into it, the answer, and what it is for. Check us. That is the point.
PAT ÷ Net Worth83.12 ÷ 448.51What the company earned on the money shareholders have in it. The headline measure of return — and the one the DuPont section takes apart.
EBIT ÷ (Net Worth + Total Borrowings)119.88 ÷ (448.51 + 110.06) = 119.88 ÷ 558.57Return on ALL the capital in the business, borrowed as well as owned. Unlike ROE, it cannot be flattered by taking on debt.
EBITDA ÷ Revenue144.57 ÷ 1,232.59Operating profitability before the effects of debt, tax and depreciation. What the business earns from the act of trading.
Total Borrowings ÷ Net Worth110.06 ÷ 448.51How much the company has borrowed against what it owns. High is not automatically bad — ask whether the borrowing is being serviced comfortably.
EBIT ÷ Finance Cost119.88 ÷ 7.98How many times over operating profit covers the interest bill. Below about 2x, a meaningful share of what the business earns is going to lenders rather than owners.
(Trade Receivables ÷ Revenue) × 365(278.69 ÷ 1,232.59) × 365How long the company waits to be paid. Rising receivable days mean revenue is being booked faster than it is collected — which is where a great many accounting problems begin.
Inventory Days + Receivable Days − Payable Days45 + 83 − 62How long cash is tied up in the operating cycle before it comes back. The longer it is, the more working capital the business must fund.
Cash from Operations ÷ PAT49.47 ÷ 83.12Did the profit turn into cash? Profit is an opinion; cash is a fact. When this sits well below 1x for long, the two are drifting apart, and the filing is where you find out why.
(PAT − Cash from Operations) ÷ Total Assets(83.12 − 49.47) ÷ 839.28 = 33.65 ÷ 839.28The share of reported profit that exists on paper rather than in the bank. It is also the heaviest single term in the Beneish model, for good reason.
Price × Post-issue Shares₹676.00 × 58,006,978 sharesWhat the whole company is being valued at, if the issue prices at the top of the band.
Market Cap + Total Borrowings − Cash3,921.27 + 110.06 − 24.07What it would actually cost to buy the whole business: you take on its debt and you get its cash. This is the number a buyer cares about, and it is the reason a P/E on its own can mislead.
Enterprise Value ÷ EBITDA4,007.27 ÷ 144.57The multiple that includes debt. Two companies on the same P/E — one debt-free, one heavily borrowed — are not the same investment, and only this number tells you so.
Market Cap ÷ PAT3,921.27 ÷ 83.12The familiar multiple. Useful, but blind to debt — read it alongside EV/EBITDA, never instead of it.
EBIT × (1 − tax rate) ÷ (Net Worth + Debt − Cash)NOPAT ÷ Invested CapitalWhat the business earns on the capital actually at work in it. We do not compare this to a cost of capital: that would need a beta, an unlisted company has none, and inventing one would be theatre.
P/E ÷ trailing PAT growth (%)47.17 ÷ 90.8%PEG was designed for FORWARD growth. This one uses TRAILING growth, because that is all a prospectus gives us — and the final year before an IPO is very often the best year the company will have for a while. A low PEG here may say more about the timing of the filing than about the price. We show it because it was asked for; we show the growth denominator beside it so it cannot mislead you quietly.
Workspace
The post-issue share count is stated as “[•]” in this filing until final pricing, so we derive it: profit after tax divided by earnings per share gives the pre-issue count, and the fresh issue divided by the offer price gives the new shares. Everything below rests on that derivation. It is close, not exact.
The numbers are already loaded. Move the offer price and watch every multiple move with it. Set your own growth and margin and see what they imply two years out. These are your assumptions, not our forecast — we have no view on what this company will earn, and the moment we published one we would be doing something we are not registered to do. What we can do is put the arithmetic in front of you and get out of the way.
Price defaults to the top of the band. Margin defaults to what the company actually reported in FY26.
Projections are arithmetic on the inputs you typed. They are not a forecast, not a recommendation, and not a view on whether this offer is worth taking. Educational only.
Institutional Alpha: DRHP Deep Dive
The global chemicals industry expanded to USD 6.2 trillion in CY25 and is projected to reach USD 7.8 trillion by CY29, with the specialty chemicals segment expected to reach a 21-23% market share. The global specialty chemicals market was valued at USD 1,240 billion in CY25 and is projected to reach USD 1,748 billion by CY29, growing at a CAGR of 9.0%. Domestically, the Indian specialty chemicals market reached ₹ 5,563 billion in FY26 and is projected to grow at a CAGR of 10-12% to reach ₹ 7,541 billion by FY29. This growth is propelled by domestic consumption, rising exports, and expanding application industries such as pharmaceuticals, agrochemicals, home care, and performance chemicals.
Future Planning
Prasol is planning to set up a new chemical manufacturing plant at Saykha Industrial Area, Gujarat. It has acquired several acres of land from GIDC and incorporated a wholly-owned subsidiary, PAPL, for this purpose (PAPL was voluntarily struck off on July 22, 2025, after which the parent company took over the direct development of the Gujarat project with no transactions recorded in PAPL post March 31, 2025).
Source: p. 333, p. 434Competitive Position
Prasol is the sole manufacturer of isophorone in India with an installed capacity of 9,000 MTPA. This gives the company a strong import-substitution position in the domestic market, serving as a significant competitive moat against other specialty chemical companies.
Source: p. 289Execution Track Record
While the company has built an aggregate installed capacity of 98,644 MTPA across Khopoli and Mahad facilities, it has experienced execution delays. The project at Khopoli was temporarily suspended due to change in scope, and several new product development and storage projects were extended beyond planned timelines to accommodate better specifications.
Source: p. 45, p. 334Shareholding, Syndicate & Leadership
Leadership & Skin in the Game
Leadership: Gaurang Natwarlal Parikh
Litigation: Outstanding litigation against the Company includes 9 tax cases (direct tax: 4 cases of ₹ 0.57 crore; indirect tax: 5 cases of ₹ 3.78 crore), 16 statutory/regulatory proceedings (aggregate ₹ 6.18 crore) and 1 material civil litigation (₹ 1.24 crore). Outstanding litigation against Promoters includes 6 criminal proceedings, 4 tax proceedings (₹ 2.80 crore) and 1 statutory/regulatory proceeding (all against Gaurang Natwarlal Parikh except 1 police complaint against Pankil Nishith Dharia with a fine of ₹ 1,250). Outstanding litigation against Directors includes 2 direct tax cases (₹ 0.60 crore).
Auditor / RPT Flags: The Statutory Auditors' report on the Audited Financial Statements for FY26 and Audited Consolidated Financial Statements for FY25 and FY24 contains emphasis of matter regarding IPO expenses of ₹ 2.92 crore in FY26 and excess managerial remuneration of ₹ 2.24 crore in FY24, along with modified opinions on internal financial controls over financial reporting regarding inventory records and overhead allocation for all three years.
Peers & Valuation
| Company | P/E | P/B | RoE | Margin |
|---|---|---|---|---|
| Aarti Industries Limited | 46.79 | — | — | EBITDA Margin: 14.17%, PAT Margin: 5.06% |
| Atul Limited | 28.04 | — | — | EBITDA Margin: 16.53%, PAT Margin: 10.99% |
| Laxmi Organic Industries Limited | 59.95 | — | — | EBITDA Margin: 6.01%, PAT Margin: 2.79% |
| Vinati Organics Limited | 30.95 | — | — | EBITDA Margin: 29.36%, PAT Margin: 19.93% |
| Privi Speciality Chemicals Limited | 42.67 | — | — | EBITDA Margin: 25.21%, PAT Margin: 12.35% |
| Yasho Industries Limited | 206.68 | — | — | EBITDA Margin: 17.04%, PAT Margin: 3.04% |
| Excel Industries Limited | 17.12 | — | — | EBITDA Margin: 12.06%, PAT Margin: 6.91% |
At the ₹676 upper band, the issue is priced at 47.2x earnings — a 11% premium to the peer median of 42.7x. This is the arithmetic of the price band against the peers the filing itself lists; it is not a view on whether the offer is worth taking.
🔍 Forensic Findings — What the Footnotes Say
Findings from across the filing — the notes, MD&A, related-party disclosures, contingent liabilities, CARO and litigation, alongside the risk section itself. Each carries where it was found, so you can see which were buried and which were disclosed. Findings marked derived are computed from the filed numbers against a stated rule, shown beside them.
Prasol has recorded ₹ 2.92 crore of IPO-related expenses under 'Other Current Assets' instead of expensing it. It intends to charge it directly to the Securities Premium Account post-IPO. The statutory auditor has flagged this as an Emphasis of Matter.
p. 32In FY24, the total managerial remuneration of ₹ 6.86 crore paid was in excess of limits specified under Section 197 read with Schedule V of the Companies Act, 2013 by ₹ 2.237 crore. The excess was subsequently approved by shareholders at the AGM.
p. 33The Statutory Auditor has issued modified opinions on internal financial controls over financial reporting for FY26, FY25, and FY24, stating that the company needs to strengthen controls over the maintenance of quantitative item-wise details, corresponding values of inventory, and allocation of overheads.
p. 32Secretarial and corporate records relating to changes in share capital, return of buybacks (extinguished in 2002 and 2004), acquisitions/transfers of equity shares by Promoters, and resolutions for appointment of certain Directors are untraceable. Practicing Company Secretary Devendra Vasant Deshpande confirmed they could not be found.
p. 111Managing Director and Promoter Gaurang Natwarlal Parikh faces 6 criminal complaints filed by the Deputy Director of Industrial Safety & Health (DISH) for factories violations, including chlorine/H2S gas leakages and an industrial accident at the Mahad facility. He has had to apply for bail.
p. 471The company purchased a land parcel adjoining its Khopoli facility from Dhaval Nalin Parikh (Joint MD and Promoter) on January 20, 2022, for ₹ 4.41 crore to comply with environmental green belt requirements.
p. 346Outstanding litigation against the Company includes 9 tax cases (direct tax: 4 cases of ₹ 0.57 crore; indirect tax: 5 cases of ₹ 3.78 crore), 16 statutory/regulatory proceedings (aggregate ₹ 6.18 crore) and 1 material civil litigation (₹ 1.24 crore). Outstanding litigation against Promoters includes 6 criminal proceedings, 4 tax proceedings (₹ 2.80 crore) and 1 statutory/regulatory proceeding (all against Gaurang Natwarlal Parikh except 1 police complaint against Pankil Nishith Dharia with a fine of ₹ 1,250). Outstanding litigation against Directors includes 2 direct tax cases (₹ 0.60 crore).
p. 2, p. 32, p. 74, p. 466, p. 472The Statutory Auditors' report on the Audited Financial Statements for FY26 and Audited Consolidated Financial Statements for FY25 and FY24 contains emphasis of matter regarding IPO expenses of ₹ 2.92 crore in FY26 and excess managerial remuneration of ₹ 2.24 crore in FY24, along with modified opinions on internal financial controls over financial reporting regarding inventory records and overhead allocation for all three years.
p. 2, p. 32, p. 74, p. 466, p. 472Short-term borrowings of ₹63.06 cr against cash of ₹24.07 cr. Debt that must be refinanced within a year is comfortable only while lenders stay comfortable.
rule: cash < 0.5x short-term debtCompany's Claims vs Reality
We stress-test each claim against the filing's own data.
Reviewed loan agreements and auditor certificates. Acuite Ratings reaffirmed ACUITE A+/Stable and ACUITE A1+ on long-term and short-term debt, and the Auditor's loan utilization certificate confirmed loans were utilized for their sanctioned purposes with zero defaults in repayments.
p. 114, p. 190Audit committee and board approvals are documented. The land purchase from Dhaval Nalin Parikh (₹ 4.41 crore) was backed by an independent valuer's report. However, the FY24 managerial remuneration did exceed statutory limits before subsequent AGM regularisation, showing partial operational non-compliance.
p. 42, p. 346, p. 432Evaluated litigation against the board's materiality threshold of ₹ 2.414 crore. Total litigation against the company is ₹ 6.18 crore (statutory/regulatory) and ₹ 4.34 crore (tax), which collectively exceeds the materiality threshold. Promoters face an additional ₹ 2.80 crore in disputes, and the MD faces criminal prosecutions.
p. 22, p. 29Proprietary SWOT — Company-Specific
Strengths
- Sole manufacturer of isophorone in India with an installed capacity of 9,000 MTPA
- Forward-integrated operations with acetone and phosphorus specialty chemical value chains
- Diversified customer base of 1,618 customers across application industries like performance chemicals, PICA, pharmaceuticals, and agrochemicals
Weaknesses
- Persistent weaknesses in internal financial controls over quantitative inventory tracking and overhead allocation
- Historically volatile cash flows from operating activities
- High dependency on imported raw materials, being the largest importer of acetone and among the top five of yellow phosphorus in India
Opportunities
- Setting up a new manufacturing facility at Saykha, Gujarat on acquired land to expand capacity and enter new product markets
- Domestic import substitution opportunities for isophorone and other specialty chemicals currently imported into India
- Global specialty chemicals market expansion projected to reach USD 1,748 billion by CY29 at a 9.0% CAGR
Threats (material, not boilerplate)
- Strict environmental regulations and risk of plant shutdowns due to pollution or hazardous emissions leaks (e.g. MPCB show cause notices for Savitri river pollution) risk_section
Why it matters: Plant closure or regulatory action can lead to material supply disruptions, revenue loss, and reputational damage - Industrial safety accidents and prosecution of key management (e.g. DISH criminal complaints against Gaurang Natwarlal Parikh for chlorine and H2S leaks) risk_section
Why it matters: Can result in civil and criminal liability for promoters, factory suspension, and negative publicity - Raw material price volatility and supply disruptions of imported acetone and yellow phosphorus risk_section
Why it matters: Directly impacts operating EBITDA margins as material costs constitute over 68.8% of total expenses
Allotment Status
Check your allotment on the registrar's portal → Registrar: KFin Technologies
Allotment is decided by the registrar, not by us and not by the exchange. In an oversubscribed retail book, allotment is by lottery, so a large application does not improve your odds beyond one lot. If money stays blocked after the refund date, the mandate expiry (22 Oct 2026) is the date to raise with your bank.
Analyst Q&A: Burning Questions
Facts from the filing. No recommendation — that layer arrives once our Research Analyst registration is live.
Why is a cash-rich firm with ₹ 24.07 crore of cash on hand raising ₹ 80 crore in fresh equity, and why is most of the ₹ 500 crore issue an Offer for Sale (OFS)?
The fresh issue is ₹ 80 crore, out of which ₹ 60 crore is allocated to repay existing term loans to optimize debt-equity ratios and save on interest costs (which stood at ₹ 7.98 crore in FY26). The remaining ₹ 420 crore is an OFS by the promoters and promoter group, allowing them to cash out a portion of their holdings (they hold 89.20% pre-offer) without the funds flowing back to the company for capital investment.
p. 87, p. 188What is the extent of supplier concentration risk for Prasol's raw materials, and who are these suppliers?
Supplier concentration is extremely high. The top 10 suppliers accounted for 68.87% (₹ 474.13 crore) of the raw materials consumed in FY26, and the top 3 suppliers accounted for 39.75% (₹ 273.69 crore). Crucially, the names of these top suppliers are omitted from the RHP due to 'commercial sensitivities of disclosure.' null of them are disclosed as related parties.
p. 58, p. 302Why did the company's EBITDA margins drop in FY25 compared to peer averages, and is the recovery in FY26 sustainable?
Profitability is highly sensitive to raw material import costs (acetone and yellow phosphorus). In FY25, margins were compressed due to raw material price escalation. While standalone Operating EBITDA margins recovered to 11.30% in FY26, this is still significantly lower than peers like Vinati (29.36%) and Privi (25.21%), and any future supply chain disruption or rupee depreciation poses a major threat to sustainability.
p. 203, p. 206What are the material regulatory and operational compliance risks arising from the multiple toxic gas leaks and safety audits?
The company has a history of toxic leaks at its Mahad plant, including a chlorine leak on August 9, 2023, and a hydrogen sulphide (H2S) leak on October 5, 2023, which resulted in fatalities and hospitalizations. These have led to 6 pending criminal cases against Managing Director Gaurang Natwarlal Parikh and show-cause notices from DISH and MPCB. Any adverse court ruling or repeat incident could result in permanent plant shutdowns and criminal liabilities.
p. 22, p. 32, p. 471Reading the Offer Structure
84% offer for sale — and the company does not appear to need the cash.
A high offer-for-sale share is not automatically a concern. On the disclosed numbers this company is profitable and not heavily borrowed, so the listing reads as an exit route for existing shareholders and a route to a public market rather than a funding exercise. Large, cash-generative companies routinely list this way.
What Earlier Investors Paid
Early capital takes real risk and is fairly rewarded for it — a large multiple built over many years is normal. What deserves a closer look is a steep step-up in a short window: a round priced cheaply only months before the offer.
| Shareholder | Priced at | When | vs IPO price |
|---|---|---|---|
| Initial Subscription and Further Issue | ₹10.00 | 1993-02-25 | 67.6x |
| An early round from roughly 34 years ago, at roughly 67.6x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Further Issuance | ₹10.00 | 1994-04-01 | 67.6x |
| An early round from roughly 33 years ago, at roughly 67.6x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Further Issuance | ₹10.00 | 1995-02-21 | 67.6x |
| An early round from roughly 32 years ago, at roughly 67.6x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Further Issuance | ₹10.00 | 1995-03-16 | 67.6x |
| An early round from roughly 32 years ago, at roughly 67.6x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Further Issuance | ₹10.00 | 1996-02-23 | 67.6x |
| An early round from roughly 31 years ago, at roughly 67.6x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Buy back | ₹30.00 | 2002-03-07 | 22.5x |
| An early round from roughly 25 years ago, at roughly 22.5x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Buy back | ₹30.00 | 2003-10-13 | 22.5x |
| An early round from roughly 23 years ago, at roughly 22.5x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Buy back | ₹30.00 | 2004-03-01 | 22.5x |
| An early round from roughly 23 years ago, at roughly 22.5x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Rights issue (1:4) | ₹50.00 | 2007-07-12 | 13.5x |
| An early round from roughly 19 years ago, at roughly 13.5x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Rights issue (1:4) | ₹60.00 | 2009-12-10 | 11.3x |
| An early round from roughly 17 years ago, at roughly 11.3x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Rights issue (2:15) | ₹125.00 | 2012-02-21 | 5.4x |
| An early round from roughly 15 years ago, at roughly 5.4x the offer price. A multiple of that size built over that long reflects the risk taken and the time elapsed. That is the normal reward for early capital, not a red flag. | |||
| Private Placement | ₹400.00 | 2016-10-17 | 1.7x |
| Buy back | ₹400.00 | 2017-07-12 | 1.7x |
| Stock Split (Sub-division 1:5) | — | 2021-12-08 | — |
| Bonus Issue (3:1) | — | 2022-01-18 | — |
Prices are as stated in the filing’s allotment history and are not adjusted for later bonus issues or share splits. Where a company has issued bonus shares, the multiples above understate the true return and can even read as losses. Adjusting for that is on our list; until it is done we would rather show the raw disclosure and tell you its limits than publish a confident number that is wrong.
Lock-in Expiry Calendar
Shares held before the IPO cannot be sold immediately; they unlock in tranches. When a tranche unlocks, more shares become eligible to trade. Retail investors are frequently caught unaware by these dates. The schedule below follows from the listing date; quantities are shown only where the filing discloses them.
- 16 Sep 2029Promoter Minimum Contribution3 years
- 16 Sep 2027Promoter Excess Shareholding1 year
- 16 Mar 2027Pre-Offer Capital (Other than Promoter Contribution)6 months
An unlock means more shares may be sold — not that they will be, and not that the price will move. We state the dates; what you do with them is your call.
What Changed Between the DRHP and the RHP
Companies file a draft prospectus, then a final one. The changes in between are rarely reported, and they can be revealing.
| Item | In the DRHP | In the RHP / Addendum |
|---|---|---|
| Reporting Period Reporting periods updated to reflect the full financial year 2026 as Standalone (since the sole subsidiary was struck off) and historical comparative periods. | Three months ended June 30, 2025, and Fiscals 2025, 2024, 2023 | Fiscals 2026 (Standalone), 2025, and 2024 (Consolidated) |
| Restated Financials RHP updated with complete audited Standalone financial statements for the year ended March 31, 2026. Overlapping year figures (FY25 and FY24) remained consistent with DRHP. | Not available (financials only up to June 30, 2025) | Newly added Standalone FY26 financials (Revenue of ₹ 1232.59 Crore and PAT of ₹ 83.12 Crore) |
| Offer for Sale Total OFS size remained ₹ 420.00 Crore. Due Jatin Narendra Parikh's passing on August 24, 2026, their shares were not transmitted, and both Jatin Narendra Parikh and Chamak Jatin Parikh were removed as selling shareholders, with their allocations redistributed. | Includes Jatin Narendra Parikh (₹ 12.00 Crore) and Chamak Jatin Parikh (₹ 12.00 Crore) among 22 selling shareholders | Jatin Narendra Parikh and Chamak Jatin Parikh removed; remaining 20 selling shareholders' portions adjusted (e.g., Gaurang Natwarlal Parikh increased to ₹ 35.36 Crore, Gaurang Natwarlal Parikh HUF decreased to ₹ 18.54 Crore) |
| Contingent Liabilities Aggregate contingent liabilities increased from ₹ 8.52 Crore in June 2025 to ₹ 10.02 Crore in March 2026, driven primarily by higher unhedged bank guarantees and DRI customs claims. | ₹ 8.52 Crore (as of June 30, 2025), comprising DRI claims of ₹ 0.36 Crore, income tax appeals of ₹ 0.18 Crore, and guarantees of ₹ 7.98 Crore | ₹ 10.02 Crore (as of March 31, 2026 Standalone), comprising DRI claims of ₹ 0.68 Crore, income tax appeals of ₹ 0.18 Crore, and guarantees of ₹ 9.15 Crore |
| Risk Factors Risk factors were reordered to prioritize and bring critical operational facility-dependency and environmental/safety risks (such as toxic gas leaks and industrial accidents) to the front. | Risk 1 was client/end-consumer product reliance; Hazardous chemical handling/accident risk was listed as Risk 9 | Risk 1 is reliance on manufacturing facilities (Khopoli/Mahad); Hazardous chemical handling/accident risk promoted to Risk 2 |
| Use of Proceeds While the borrowing repayment object allocation remained ₹ 60.00 Crore, the evaluation date of loans and prepayment penalty terms (up to 2% p.a.) were updated to reflect July 15, 2026. | Debt outstanding evaluated as of August 31, 2025 (₹ 296.11 Crore outstanding of ₹ 454.10 Crore sanctioned) | Debt outstanding evaluated as of July 15, 2026 (₹ 343.67 Crore outstanding of ₹ 650.90 Crore sanctioned) |
| Litigation Tax disputes against the Company decreased from 13 to 9, while statutory proceedings increased. Criminal cases against Promoters increased from 5 to 6 due to a new summary criminal case filed by the Deputy Director of Industrial Safety & Health (DISH) on October 14, 2025. | Litigations against Company: 13 tax cases and 6 statutory/regulatory proceedings (₹ 15.46 Crore total); against Promoters: 5 criminal and 4 tax cases | Litigations against Company: 9 tax cases and 16 statutory/regulatory proceedings (₹ 6.18 Crore total); against Promoters: 6 criminal, 4 tax, and 1 statutory/regulatory proceeding |
| Statutory Dues Disclosures on statutory dues payments (provident fund deposits) were updated with revised counts and delayed amounts as per the updated audit reports. | EPF delays: 2 instances in FY25 (₹ 0.04 million = ₹ 0.004 Crore), 1 instance in FY24 (₹ 0.02 million = ₹ 0.002 Crore) | EPF delays: 2 instances in FY25 (₹ 0.06 million = ₹ 0.006 Crore), 2 instances in FY24 (₹ 0.07 million = ₹ 0.007 Crore), and 3 instances in FY26 (negligible) |
Educational, grounded entirely in the company's filings (DRHP/RHP). Not investment advice. FinMinutes does not provide buy/sell recommendations.